NEW YORK, Jan. 30, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Chinese Pharmaceutical Market 2012-2022http://www.reportlinker.com/p0151197/Chinese-Pharmaceutical-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Report Details
Where is the pharma market in China heading? Visiongain's report shows you its potential revenues to 2022, discussing opportunities and developments.
Discover sales predictions at overall market and submarket levels. Our study gives you business research, analysis and opinion for drug sales in China. Find data and trends there.
See how Chinese submarkets can perform to 2022 - patented brands, generics, OTC products, traditional medicines, anti-infectives, vaccines, cardiovascular/cerebrovascular, alimentary/metabolic, cancer and CNS drugs. You view potential revenues, with discussions.
How will governmental reform of the healthcare system affect the pharmaceutical industry? Will patented branded products achieve greater market penetration this decade?
Opportunities multiply. The government's Healthy China 2020 plan will mean up to $1.4 trillion invested. See the effects of rising purchase power and widening medical coverage, discovering prospects from 2012. You find information, calculations and views in this report.
Medical R&D in China is gaining prominence. Assess the trends behind its emergence as a biopharmaceutical hub, reviewing progress in outsourced research and manufacturing.
The report discusses many domestic companies, such as China National Biotec Group, Sinopharm, WuXi AppTec, Sinovac Biotech and Beijing Pharmaceutical Group. Biopharma industry is flourishing.
View activities of multinationals too, including Pfizer, Sanofi, Bayer, AstraZeneca, Roche, Novartis, GSK, Merck, Eli Lilly and Novo Nordisk. This is the country to watch for developments in healthcare. Our investigation shows you why.
Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You can find answers now in our work.
Revenue forecasts, market shares, developmental trends, discussions and interviews
In the report, you find revenue forecasting, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), opinions and news. You receive 72 tables and charts and two research interviews.
Advantages of Chinese Pharmaceutical Market 2012-2022 for your work
In particular, this study gives you the following knowledge and benefits:• Find revenue predictions to 2022 for the overall Chinese pharma market and submarkets, seeing revenue growth• Read sections on 40 prominent companies there, viewing developments in biotechnology and other aspects of medicine• Investigate competition and opportunities influencing sales results• Find out what will stimulate and restrain the market, affecting its growth• See emerging trends in biopharma R&D, contract research and manufacturing• Appraise therapeutic and commercial needs, as well as healthcare policy• View opinions from our survey of authorities on the sector.
There, you receive a distinctive mix of quantitative and qualitative work with independent predictions. We analyse activities and events, helping you to stay ahead.
Gain pharma business research, data and analysis for the leading emerging countryVisiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6
Table of Contents1.1 China: Pharmaceutical Market Review
1.2 Contents of this Report
1.3 Research and Analysis Methods
2. Chinese Pharmaceutical Market: An Overview2.1 China: National Overview2.1.1 China's Rise as an Economic Superpower2.2 From Maoism to Market: Chinese Healthcare Since World War II2.2.1 Socialised Healthcare2.2.2 Developments Since 19922.2.3 Investment, But Healthcare Disparities Remain2.3 The Rise of the Chinese Pharmaceutical Market2.3.1 Picking up the Tab2.4 Healthy China 2020: 'Unprecedented in Human History'2.4.1 Achievements and Potential of the Healthy China 2020 Initiative2.5 Demography and Disease Burden in China2.5.1 The Ageing Population2.5.2 Obesity in China2.5.3 Stroke, Heart Disease and Diabetes2.5.4 Cancer and Respiratory Diseases2.5.5 Communicable Diseases2.6 Other Aspects of the Chinese Market
3. The Chinese Pharmaceutical Market, 2012-2022
3.1 Chinese Pharmaceutical Market: Forecast, 2012-2022
3.2 The Product Mix in China, 2010
3.3 The Product Mix in China, 2012-2022
3.4 Prescribed Patented Brands: Forecast, 2012-2022
3.4.1 Drivers and Restraints for Patented Prescription Drugs
3.5 Prescribed Generics: Forecast, 2012-2022
3.5.1 Drivers and Restraints for Prescribed Generics
3.6 OTC Products: Forecast, 2012-2022
3.6.1 Drivers and Restraints for OTC Products
3.7 TCM Products: Forecast, 2012-2022
3.7.1 Drivers and Restraints for TCM Products
4. Leading Therapeutic Areas in the Chinese Market, 2012-20224.1 Anti-Infectives Market, 2012-20224.1.1 Antibiotics: China's Drugs of Choice4.1.2 Antivirals: a Growth Area 4.2 Cancer Treatments Market, 2012-20224.2.1 Small Molecules Dominate the Chinese Cancer Drug Market4.3 Cardiovascular/Cerebrovascular Market, 2012-20224.3.1 Anti-Aggregants, Statins and Vasotherapeutics4.4 Alimentary and Metabolic Diseases Market, 2012-20224.4.1 Antiulcerants and Diabetes Treatments4.5 Central Nervous System Diseases Market, 2012-20224.5.1 Pain Relief4.5.2 Anti-Depressants4.5.3 Neurodegenerative Diseases4.6 Vaccines Market, 2012-20224.6.1 Opportunities and Challenges in Vaccines 4.7 Other Therapeutic Classes Market, 2012-2022
5. China as a Pharmaceutical Hub, 2012-2022
5.1 China as a Manufacturing Hub
5.1.1 China's API Export Market
5.1.2 Contract Manufacturing Organisations: Beyond APIs
5.2 China as a Research Hub
5.2.1 Clinical Trials in China
5.2.2 The Rise of China's Contract Research Organisations
5.3 China as a Biotechnology Hub
5.3.1 Leading the Way in Biosimilars
5.3.2 Biomarkers and Genomic Sequencing
5.3.3 Stem Cells in China
5.3.4 Other Regenerative Medicine in China
5.4 China as a Pharmaceutical Hub: Conclusions
6. Key Domestic Players in the Chinese Market, 20126.1 Fragmentation and Consolidation Among Chinese Companies6.2 Summary of Leading Domestic Companies6.3 China National Pharmaceutical Corporation (Sinopharm)6.4 China National Biotec Group (CNBG)6.5 WuXi AppTec6.6 CSPC Pharmaceutical Group6.7 Beijing Pharmaceutical Group6.8 Shanghai Pharmaceutical Group (SPGC)6.9 Yangtze River Pharmaceutical Group6.10 Tianjin Pharmaceuticals Group Corporation (TJPC)6.11 Taiji Group6.12 C&O Pharmaceutical Technology Holdings6.13 Harbin Pharmaceutical Group Holding Company6.14 Guangzhou Pharmaceutical Holdings6.15 Sinovac Biotech (Beijing Kexing Bioproducts)6.16 Tongrengtang Pharmaceutical6.17 Buchang Pharmaceutical6.18 Northeast Pharmaceutical Group (NEPG)6.19 China Nepstar Chain Drugstore6.20 Zhejiang Huahai Pharmaceuticals6.21 Hangzhou Zhongmei Huadong Pharmaceutical6.22 Hualan Biological Engineering6.23 China Sky One Medical6.24 Zensun (Shanghai) Sci & Tech6.25 Ascletis6.26 Shangdong Dong-E-E-Jiao6.27 Mindray Medical International and China Medical Technologies
7. Key Multinational Players in the Chinese Market, 2012
7.1 Bayer Schering
7.2 AstraZeneca
7.3 Pfizer
7.4 Sanofi
7.5 Roche
7.6 Novartis
7.7 GlaxoSmithKline
7.8 Merck & Co.
7.9 Novo Nordisk
7.10 Eli Lilly
7.11 Abbott Laboratories
7.12 Johnson & Johnson
7.13 Bristol-Myers Squibb
7.14 Teva Pharmaceutical Industries
7.15 Takeda
8. The Chinese Pharma Market: Qualitative Analysis8.1 Strengths: Government Investment Will Further Expand this Dynamic Market8.2 Weaknesses: IP and Regulatory Challenges Remain8.3 Opportunities: The Scramble for China8.4 Threats: A House Built on Sand?
9. Research Interviews
9.1 Interview with Dr Derek Lowe, Drug Discovery Expert
9.1.1 On the Rising Cost of Outsourcing Research to China
9.1.2 On Building Relationships in the Chinese Market
9.1.3 On Prospects for Western Brands in the Chinese Market
9.1.4 On IP Protection and Safety Concerns in China
9.1.5 On the Role of the Chinese State in the Pharmaceutical Market
9.1.6 On Biotechnology and the Chinese Research Culture
9.1.7 On Chinese Biosimilar Manufacturing
9.2 Interview with Dr Jean-Pierre Wery, President, Crown Bioscience, China
9.2.1 Contract Research Services Offered by Crown Bioscience
9.2.2 On Technological Platforms and Animal Models Relevant to Biomarkers
9.2.3 On the Range of Therapeutic Areas Covered by Crown Bioscience
9.2.4 On Translational Medicine and Patient Stratification
9.2.5 On the Future for Crown Bioscience and Other CROs
10. Conclusions10.1 The Chinese Pharma Market Will Continue to Grow Rapidly10.2 Treatments for Chronic Diseases Will Challenge the Anti-Infectives Sector10.3 China Will Continue to Grow as a Focus for the Multinational Industry10.4 China is Set to be the Most Important Pharmaceutical Market, Despite Weaknesses
List of Tables
Table 2.1 Causes of Mortality in China, 2002Table 3.1 Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2010-2015Table 3.2 Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2016-2022Table 3.3 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010 Table 3.4 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 3.5 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2015 Table 3.6 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 3.7 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2022 Table 3.8 Prescribed Patented Brands Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 3.9 Prescribed Patented Brands Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 3.10 Prescribed Generics Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 3.11 Prescribed Generics Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 3.12 OTC Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 3.13 OTC Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 3.14 TCM Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 3.15 TCM Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.1 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2010Table 4.2 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.3 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2015Table 4.4 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.5 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2022Table 4.6 Anti-Infectives Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.7 Anti-Infectives Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.8 Oncology Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.9 Oncology Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.10 Cardiovascular/Cerebrovascular Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.11 Cardiovascular/Cerebrovascular Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.12 Alimentary/Metabolic Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.13 Alimentary/Metabolic Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.14 CNS Diseases Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.15 CNS Diseases Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.16 Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.17 Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.18 Other Therapeutic Classes Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.19 0ther Therapeutic Classes Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 8.1 Strengths and Weaknesses in the Chinese Pharma Market, 2012-2022Table 8.2 Opportunities and Threats in the Chinese Pharma Market, 2012-2022
List of Figures
Figure 2.1 Causes of Mortality in China, 2002Figure 3.1 Chinese Pharmaceutical Market: Revenues ($bn), 2010-2015Figure 3.2 Chinese Pharmaceutical Market: Revenues ($bn), 2016-2022Figure 3.3 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010 Figure 3.4 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), 2010-2015Figure 3.5 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2015 Figure 3.6 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), 2016-2022Figure 3.7 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2022 Figure 3.8 Prescribed Patented Brands Market: Revenues ($bn), 2010-2015Figure 3.9 Prescribed Patented Brands Market: Revenues ($bn), 2016-2022Figure 3.10 Prescribed Generics Market: Revenues ($bn), 2010-2015Figure 3.11 Prescribed Generics Market: Revenues ($bn), 2016-2022Figure 3.12 OTC Products Market: Revenues ($bn), 2010-2015Figure 3.13 OTC Products Market: Revenues ($bn), 2016-2022Figure 3.14 TCM Products Market: Revenues ($bn), 2010-2015Figure 3.15 TCM Products Market: Revenues ($bn), 2016-2022Figure 4.1 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2010 Figure 4.2 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), 2010-2015Figure 4.3 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2015Figure 4.4 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), 2016-2022Figure 4.5 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2022Figure 4.6 Anti-Infectives Market: Revenues ($bn), 2010-2015Figure 4.7 Anti-Infectives Market: Revenues ($bn), 2016-2022Figure 4.8 Oncology Market: Revenues ($bn), 2010-2015Figure 4.9 Oncology Market: Revenues ($bn), 2016-2022Figure 4.10 Cardiovascular/Cerebrovascular Market: Revenues ($bn), 2010-2015Figure 4.11 Cardiovascular/Cerebrovascular Market: Revenues ($bn), 2016-2022Figure 4.12 Alimentary/Metabolic Market: Revenues ($bn), 2010-2015Figure 4.13 Alimentary/Metabolic Market: Revenues ($bn), 2016-2022Figure 4.14 CNS Diseases Market: Revenues ($bn), 2010-2015Figure 4.15 CNS Diseases Market: Revenues ($bn), 2016-2022Figure 4.16 Vaccines Market: Revenues ($bn), 2010-2015Figure 4.17 Vaccines Market: Revenues ($bn), 2016-2022Figure 4.18 Other Therapeutic Classes Market: Revenues ($bn), 2010-2015Figure 4.19 0ther Therapeutic Classes Market: Revenues ($bn), 2016-2022
Companies ListedAcambis
Agilent Technologies
American California Pharmaceutical Group
Anhui BBCA Biochemical
AppTech Laboratory Services
Ascletis
Asian Cancer Research Group
AstraZeneca
Aurobindo Pharma
AXM Pharma
Bayer Schering Pharma
Beijing Bio-Ekon Biotechnology
Beijing Double-Crane Pharmaceutical Business
Beijing GP Medical Technologies
Beijing Haiyan Pharmaceutical Company
Beijing Pharmaceutical Group
Beijing Shuanglu
Beijing Tiantan Biological Products
Beijing Union Medical College Hospital
Beijing University
Beijing Wandong Medical Equipment
Beijing Yuande Bio-Medical Engineering
BGI (formerly Beijing Genomics Institute)
Biocon
BioDura
BioMarin Pharmaceutical
Bioton
BMP Sandstone
Bristol-Myers Squibb
Broad Institute
Buchang Pharmaceutical
C&O Pharmaceutical Technology Holdings
Cai Zhi Lin Pharmacies
Cancer Therapeutics
Charles River Laboratories
China Aoxing
China Chain Stores and Franchise Association (CCSFA)
China Medical Technologies
China National Biotec Group
China National Pharmaceutical Corporation (Sinopharm)
China Nepstar Chain Drugstore
China Pharmaceutical Group (China Pharma)
China Sky One Medical
ChinaBio Therapeutics
Chinese Academy of Medical Sciences
Chinese Academy of Sciences
Chinese Diabetes Society
Chongqing Taiji Industry Group
Chongqing Tongjunge
Cipla
Cord Blood America
Covance
Crown Bioscience
Crucell Biotechnology
CSPC Pharmaceutical Group
CSPC Zhongrun
Cumencor Pharmaceuticals
Denosim
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Eisai
Eli Lilly
European Medicines Agency (EMEA/EMA)
Excel PharmaStudies
FeRx
Food and Drug Administration (FDA, US)
Frontage Laboratories
GenScript
Genzyme Corporation
GlaxoSmithKline
Goldman Sachs Group
Greater China Corporation
Guangdong Province People's Hospital
Guangzhou Medical University
Guangzhou Pharmaceutical Company
Guangzhou Pharmaceutical Holdings
Habin Tian Di Ren Medical Science and Technology
Hangzhou Sanofi-Synthelabo Minsheng
Hangzhou Zhongmei Huadong Pharmaceutical
Harbin Pharmaceutical Group
HD Biosciences
Hebei Pharmaceutical Group
Huadong Medicine Company
Hualan Biological Engineering
Hutchison MediPharma
Institute for BioMedical Research (Shanghai)
International Diabetes Foundation
Introgen Therapeutics
Ivax Corporation
Jian Min Pharmacies
Jiangsu Haici Biological Pharmacy Company
Jiangsu New Medicine Research Institution
Jiangsu Walvax Biotech
Johnson & Johnson
Knoll
LEAD Pharmaceuticals
LG Life Sciences
Lundbeck
Merck & Co.
MicuRx Pharmaceuticals
Mindray Medical International
Ministry of Commerce (China)
Ministry of Science and Technology (China)
Minsheng Pharmaceutical
Mirahi Biotech
Nanjing Hailing National Engineering Research Center
Nanjing Hailing Pharmaceutical Company
National Center for Drug Screening (China)
New England Journal of Medicine
Northeast General Pharmaceutical
Northeast Pharmaceutical Group (NEPG)
NorthEast Pharmacy Chain
NovaMed Pharmaceuticals
Novartis
Novartis China
Novo Nordisk
Nycomed Amersham
Organization for Economic Cooperation and Development (OECD)
Patheon
Pfizer
Piramal Healthcare Solutions
PlaNrt Finance
Provincial Institute for the Control of Pharmaceutical and Biologic Products (China)
Qilu Pharmaceutical
QRxPharma
Roche
Sandoz (part of Novartis)
Sanjing Pharmaceutical
Sanofi
Shandong Dong-E E-Jiao
Shanghai Zhong Hua Pharmaceutical Factory (Jiang Qiao Branch)
Shanghai ChemExplorer
Shanghai Haini Pharmaceutical Company
Shanghai Huai Hai Pharmaceutical Factory
Shanghai Institute for Biological Sciences
Shanghai Institute of Materia Medica
Shanghai Jiao Tong University
Shanghai No. 6 Pharmaceutical Factory
Shanghai Pharmaceutical Group (SPGC)
Shanghai Qisheng
Shanghai Schering-Plough
Shanghai Sunve Pharmaceutical
Shanghai Xin Hua Lian Pharmaceutical
Shenzhen Neptunus Interlong Bio-Technique
Shenzhen SiBiono GeneTech
Shijiazhuang Pharmaceutical Group
Shire Pharmaceuticals
SiBiono
Sichuan Hairong Pharmaceutical Company
Sicor Pharmaceuticals
SiniWest Holdings
Sino-American Kunming Baker Norton Pharmaceutical
Sinopharm
Sinovac Biotech (Beijing Kexing Bioproducts)
Solvay Pharmaceuticals
Southwest Pharmaceutical
State Food and Drug Administration (SFDA)
State Key Lab of Respiratory Disease
Sundia Meditech
Sunway Biotech
Suzhou Novartis Pharma Technology
Taiji Group
Takeda Pharmaceutical
Tangshan Yian Bioengineering
Teva Pharmaceutical Industries
Thermo Fisher Scientific
Tianjin International Joint Academy of Biotechnology and Medicine
Tianjin Jin Yao Group
Tianjin Medical University Cancer Hospital
Tianjin Pharmaceutical Factory
Tianjin Pharmaceuticals Group Corporation
Tianjin Takeda Pharmaceuticals
Tonghua Dongbao
Tongrentang Pharmaceutical
Tsinghua University
UNICEF
United Pharmatech
Vertex Pharmaceuticals
Weisheng Pharmaceutical
Working Group on Obesity in China
World Health Organization (WHO)
World Trade Organization (WTO)
Wuhan National Bioindustry Base Construction
WuXi AppTec
WuXi PharmaTech
Wyeth (now part of Pfizer)
Xian-Janssen Pharmaceuticals
Yangtze River Pharmaceutical Group
Yunnan Walvax BiotechJiangsu Pharmaceutical Company
Zensun (Shanghai) Sci & Tech
Zhejiang Huahai Pharmaceuticals
Zhejiang Medicine
Zhejiang Tianyuan
Zhongnuo
Zydus Cadila
To order this report:Drug and Medication Industry: Chinese Pharmaceutical Market 2012-2022Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article